SCHOTT to invest 300 million euros in pharmaceutical packaging

The Schott technology group is set to invest around 300 million euros in the next three years in the expansion of its core business of glass tubing.

The SCHOTT technology group is set to invest around 300 million euros in the next three years in the expansion of its core business of glass tubing as the starting material for pharmaceutical packaging as well as pharmaceutical packaging made of glass and polymer, reinforcing its strong belief in overall growth in demand for these products. Production capacities will be significantly increased, in Europe and Asia in particular. The group are to build new production facilities in Germany and China and expand capacity in India and Switzerland

Schott produces pharmaceutical glass tubing that is converted into approximately 25 billion pharmaceutical packages, such as vials, syringes, ampoules, or cartridges, produced by Schott and other suppliers around the world. Due to the strong demand for these products, Schott intends to further expand and strengthen its presence in Asia, as Dr Frank Heinricht, Chairman of the Board of Management explains. As a supplier, it is also contributing to further improve access to safe medication for local populations through these investments.

Projects include a new melting tank in India, the Greenfield project in China, a new production facility in Müllheim, Germany and expansion at the site in St. Gallen Switzerland.

www.schott.com